
John Ligon, M.D.
206 posts

John Ligon, M.D.
@JohnLigon
Moving #immunotherapy into early phase clinical trials. Supported by @TheVFoundation, @sitcancer,@agentsmib. Husband. Dad. Spurs fan. Hiring! https://t.co/ExOEaNuWsK






MBI researchers have received approval from @US_FDA to test two new experimental therapies in first-ever human clinical trials for Group 4 medulloblastoma, a type of malignant brain tumor in children. Read more: bit.ly/4eQ7lNo



Multilamellar RNA nanoparticle aggregates orchestrate innate and adaptive immunity to reject early and late stage murine tumors. In client-owned dogs, RNA-LPAs improved survival and reprogrammed TME. In a first-in-human trial, RNA-LPAs elicited rapid cytokine/chemokine release, immune activation/trafficking, and glioma-specific immune responses. Years of amazing teamwork now out in Cell. Thank you so much to our team members! @UFHealthCancer @ogandorivas @JohnLigon @Rosen_NeuroOnc @UFHealth @UFMBI cell.com/cell/fulltext/…










Congrats to @UFHealth neurosurgeon & MBI researcher Dr. Maryam Rahman, who received the inaugural @UFMedicine Diamond Award for professional excellence, leadership & community involvement at the @UF Women in Medicine and Science Celebration. Learn more: bit.ly/3G9zM8J








